Publications
Publications
Show Results For
- All HBS Web
(939)
- Faculty Publications (488)
- October 2009 (Revised July 2013)
- Case
Gilead Sciences, Inc.: Access Program
By: V. Kasturi Rangan and Katharine Lee
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details
- August 2009 (Revised August 2012)
- Case
Cabot Pharmaceuticals, Inc.
By: Frank V. Cespedes and John T. Gourville
Traces the 12-year career of a pharmaceutical salesperson, Bob Marsh, from recruitment to termination. Marsh has had an uneven career with Cabot Pharmaceuticals and eventually is asked to resign. Following his termination, a number of Marsh's former customers complain... View Details
- July 2009 (Revised May 2010)
- Case
Pfizer: Letter from the Chairman (A)
By: Robert L. Simons and Natalie Kindred
This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to... View Details
- June 2009 (Revised April 2017)
- Teaching Note
Merck: Managing Vioxx (A)-(G)
By: Robert Simons and Natalie Kindred
Teaching Note for [109080], [109081], [109082], [109083], [109084], [109085], and [109086]. View Details
- April 2009
- Case
Merck: Managing Vioxx (A)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
This two-class case series allows students to stand in the shoes of CEO Ray Gilmartin during the unfolding stages of a reputational crisis. Merck's mission statement claims to "put patients first," but the company is widely criticized for putting profit before patient... View Details
- April 2009 (Revised April 2010)
- Supplement
Merck: Managing Vioxx (B)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
- April 2009
- Supplement
Merck: Managing Vioxx (C)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Pharmaceutical Industry
- April 2009
- Supplement
Merck: Managing Vioxx (D)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Pharmaceutical Industry
- April 2009
- Supplement
Merck: Managing Vioxx (E)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
- April 2009 (Revised April 2010)
- Supplement
Merck: Managing Vioxx (F)
By: Robert L. Simons and Natalie Kindred
- April 2009
- Supplement
Merck: Managing Vioxx (G)
By: Robert L. Simons and Natalie Kindred
- April 2009 (Revised April 2009)
- Case
Immusol and Novartis
By: Regina E. Herzlinger, Keyne M. Monson, Juan D. Betancourt and Victor Li
Should Immusol strive to become a fully integrated pharmaceutical company? How should a small pharmaceutical company structure a deal for its novel technology with the giant Novartis? View Details
- April 2009
- Teaching Note
Amylin Pharmaceuticals: Diabetes and Beyond (TN)
By: Richard G. Hamermesh and Rachel Gordon
Teaching Note for [809011]. View Details
- March 2009
- Teaching Note
Proteus Biomedical: Making Pigs Fly (TN)
Teaching Note for [809051]. View Details
- March 2009
- Teaching Note
Antegren: A Beacon of Hope (TN)
Teaching Note for [408025], [408026], [408027], and [408028]. View Details
- February 2009 (Revised December 2009)
- Case
Merck: Global Health and Access to Medicines
By: V. Kasturi Rangan and Katharine Lee
The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its business strategy with its corporate social... View Details
- February 2009
- Teaching Note
Syndexa and Technology Transfer at Harvard University (TN)
Teaching Note for [808073]. View Details
- Article
A Blueprint for Pharmacy Benefits Managers to Increase Value
By: William Shrank, Michael E. Porter, Sachin H. Jain and Niteesh K. Choudhary
Pharmacy benefits managers (PBMs) have a unique opportunity to promote public health and generate value in the healthcare system. However, PBMs are largely evaluated on their ability to control costs rather than improve health. PBMs should be evaluated along three... View Details
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
- December 2008 (Revised October 2013)
- Case
Amylin Pharmaceuticals: Diabetes and Beyond (A)
By: Richard G. Hamermesh and Rachel Gordon
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details